Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
Identifieur interne : 000186 ( PubMed/Corpus ); précédent : 000185; suivant : 000187Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
Auteurs : Warawat ChaichanSource :
- Psychiatry and clinical neurosciences [ 1323-1316 ] ; 2004.
English descriptors
- KwdEn :
- Acute Disease, Adult, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Benzodiazepines (adverse effects), Benzodiazepines (therapeutic use), Drug Therapy, Combination, Female, Fluvoxamine (adverse effects), Fluvoxamine (therapeutic use), Hospitals, Psychiatric, Humans, Male, Middle Aged, Prospective Studies, Schizophrenia (diagnosis), Schizophrenia (drug therapy), Schizophrenic Psychology, Serotonin Uptake Inhibitors (adverse effects), Serotonin Uptake Inhibitors (therapeutic use), Thailand, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Benzodiazepines, Fluvoxamine, Serotonin Uptake Inhibitors.
- chemical , therapeutic use : Antipsychotic Agents, Benzodiazepines, Fluvoxamine, Serotonin Uptake Inhibitors.
- geographic : Thailand.
- diagnosis : Schizophrenia.
- drug therapy : Schizophrenia.
- Acute Disease, Adult, Drug Therapy, Combination, Female, Hospitals, Psychiatric, Humans, Male, Middle Aged, Prospective Studies, Schizophrenic Psychology, Treatment Outcome.
Abstract
The objective of the present study was to compare the efficacy and adverse effects of olanzapine plus fluvoxamine and those of olanzapine alone, in schizophrenic patients with acute exacerbation. A randomized, placebo-controlled, 6-week trial was carried out at a University Hospital in Bangkok, Thailand. The efficacy and adverse effects were assessed biweekly by using the Brief Psychiatric Rating Scale (BPRS) and the Udvalg for Kliniske Undersogelser side-effect scale, respectively. Twenty schizophrenic patients with acute exacerbation were randomly assigned to receive olanzapine plus fluvoxamine or olanzapine alone. The study found that the means of BPRS total and BPRS general psychopathology score changes were significantly larger in olanzapine plus fluvoxamine group (P = 0.037 and P = 0.045, respectively). The incidence of treatment adverse effects is comparable. In conclusion, the study findings suggest that fluvoxamine augmentation to olanzapine is well tolerated and more effective than olanzapine alone for short-term (6-week) treatment of an acute exacerbation of schizophrenia. Due to a number of limitations, further studies are warranted to confirm.
DOI: 10.1111/j.1440-1819.2004.01269.x
PubMed: 15298648
Links to Exploration step
pubmed:15298648Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.</title><author><name sortKey="Chaichan, Warawat" sort="Chaichan, Warawat" uniqKey="Chaichan W" first="Warawat" last="Chaichan">Warawat Chaichan</name><affiliation><nlm:affiliation>Nakhonsawan Psychiatric Hospital, Nakhonsawan, Thailand. psychi@mozart.inet.co.th</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15298648</idno><idno type="pmid">15298648</idno><idno type="doi">10.1111/j.1440-1819.2004.01269.x</idno><idno type="wicri:Area/PubMed/Corpus">000186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.</title><author><name sortKey="Chaichan, Warawat" sort="Chaichan, Warawat" uniqKey="Chaichan W" first="Warawat" last="Chaichan">Warawat Chaichan</name><affiliation><nlm:affiliation>Nakhonsawan Psychiatric Hospital, Nakhonsawan, Thailand. psychi@mozart.inet.co.th</nlm:affiliation></affiliation></author></analytic><series><title level="j">Psychiatry and clinical neurosciences</title><idno type="ISSN">1323-1316</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Disease</term><term>Adult</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Benzodiazepines (adverse effects)</term><term>Benzodiazepines (therapeutic use)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Fluvoxamine (adverse effects)</term><term>Fluvoxamine (therapeutic use)</term><term>Hospitals, Psychiatric</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Schizophrenia (diagnosis)</term><term>Schizophrenia (drug therapy)</term><term>Schizophrenic Psychology</term><term>Serotonin Uptake Inhibitors (adverse effects)</term><term>Serotonin Uptake Inhibitors (therapeutic use)</term><term>Thailand</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Benzodiazepines</term><term>Fluvoxamine</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Benzodiazepines</term><term>Fluvoxamine</term><term>Serotonin Uptake Inhibitors</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Thailand</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Acute Disease</term><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Hospitals, Psychiatric</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Schizophrenic Psychology</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of the present study was to compare the efficacy and adverse effects of olanzapine plus fluvoxamine and those of olanzapine alone, in schizophrenic patients with acute exacerbation. A randomized, placebo-controlled, 6-week trial was carried out at a University Hospital in Bangkok, Thailand. The efficacy and adverse effects were assessed biweekly by using the Brief Psychiatric Rating Scale (BPRS) and the Udvalg for Kliniske Undersogelser side-effect scale, respectively. Twenty schizophrenic patients with acute exacerbation were randomly assigned to receive olanzapine plus fluvoxamine or olanzapine alone. The study found that the means of BPRS total and BPRS general psychopathology score changes were significantly larger in olanzapine plus fluvoxamine group (P = 0.037 and P = 0.045, respectively). The incidence of treatment adverse effects is comparable. In conclusion, the study findings suggest that fluvoxamine augmentation to olanzapine is well tolerated and more effective than olanzapine alone for short-term (6-week) treatment of an acute exacerbation of schizophrenia. Due to a number of limitations, further studies are warranted to confirm.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15298648</PMID><DateCreated><Year>2004</Year><Month>08</Month><Day>09</Day></DateCreated><DateCompleted><Year>2004</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1323-1316</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin. Neurosci.</ISOAbbreviation></Journal><ArticleTitle>Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.</ArticleTitle><Pagination><MedlinePgn>364-8</MedlinePgn></Pagination><Abstract><AbstractText>The objective of the present study was to compare the efficacy and adverse effects of olanzapine plus fluvoxamine and those of olanzapine alone, in schizophrenic patients with acute exacerbation. A randomized, placebo-controlled, 6-week trial was carried out at a University Hospital in Bangkok, Thailand. The efficacy and adverse effects were assessed biweekly by using the Brief Psychiatric Rating Scale (BPRS) and the Udvalg for Kliniske Undersogelser side-effect scale, respectively. Twenty schizophrenic patients with acute exacerbation were randomly assigned to receive olanzapine plus fluvoxamine or olanzapine alone. The study found that the means of BPRS total and BPRS general psychopathology score changes were significantly larger in olanzapine plus fluvoxamine group (P = 0.037 and P = 0.045, respectively). The incidence of treatment adverse effects is comparable. In conclusion, the study findings suggest that fluvoxamine augmentation to olanzapine is well tolerated and more effective than olanzapine alone for short-term (6-week) treatment of an acute exacerbation of schizophrenia. Due to a number of limitations, further studies are warranted to confirm.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaichan</LastName><ForeName>Warawat</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Nakhonsawan Psychiatric Hospital, Nakhonsawan, Thailand. psychi@mozart.inet.co.th</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>132539-06-1</RegistryNumber><NameOfSubstance UI="C076029">olanzapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001569">Benzodiazepines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016666">Fluvoxamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006778">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D012565">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017367">Serotonin Uptake Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013785">Thailand</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>10</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15298648</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2004.01269.x</ArticleId><ArticleId IdType="pii">PCN1269</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/MozartV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000186 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000186 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= MozartV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15298648
|texte= Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15298648" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MozartV1
| This area was generated with Dilib version V0.6.20. |  |